Access to innovative medicine
The call for access to medicine affects not only developing and emerging countries but also countries without state-run health insurance systems, such as the United States. Here, too, many people cannot afford certain effective medicines when they come at a higher cost as a result of the high associated research outlay.
For markets like these, Bayer has developed a differential pricing system based on the general level of income, with the medicines being distributed for sale via local partners. This way, for example, a total of 40,366 patients in the United States benefited in 2011 from our patient access programs, including 17,068 from our multiple sclerosis drug Betaseron™/Betaferon™, 39 from Kogenate™ for the treatment of hemophilia, and 2,975 from the anticancer drug Nexavar™. Similar programs have been up and running since 2007 in China and, since 2008, in other countries in southern and southeast Asia, Brazil and selected countries in southeastern Europe.
Programs like these not only provide patients with access to forms of treatment they could otherwise not afford – they also help Bayer to open up new markets.
We intend to further expand Bayer’s commitment in this area in the future. To ensure the long-term success of our programs, our concepts within the ATM strategy must be commercially viable, they must offer answers to urgent social issues and they must comply with the principles of research-driven pharmaceutical manufacturers. In line with the joint declaration – the “Principal Focus and Actions of the Research-Based Pharmaceutical Industry in Contributing to Global Health” – all member companies of the International Pharmaceutical Association are committed to supporting the Millennium Development Goals. The formation of global partnerships plays an essential role in this regard.
Bayer is also active in the public health sector, e.g. with its “Go West” [ 27 ]
program in China that was launched in 2007 in cooperation with the Chinese Health Ministry to support the continuing education of physicians in rural and district hospitals in the undersupplied western part of the country.
|Bayer lighthouse projects for health care|
|Family Planning||Implemented measures||Results in 2011|
|Introduce original products oral contraceptives) at prices in line with the local market in 11 African countries jointly |
with USAID by 2013
|Project: Contraceptive Security Initiative (CSI): Ethiopia (Dec. 2010), Uganda (Sept. 2011) and Tanzania (Nov. 2011), with another eight countries to follow by 2013 (contract with USAID to run until 2014 – roll-out scheduled for completion in 2012)||Measurements are based on CYP* (Couple Years of Protection) |
Example for oral contraceptives: 1 CYP = around 14 cycle packs; total CYPs: 8,157;
all CYPs are calculated using the MSI Impact Calculator** (Version 1.2)
Ethiopia (2011): outlets supplied***: 1,351; cycles provided: 103,690;
Uganda (2011): outlets supplied: 140; cycles provided: 7,429; CYPs: 530 Tanzania (2011): outlets supplied: 47; cycles provided: 3,097; CYPs: 221
|Increase annual provision of oral contraceptives to 119 million cycles jointly with partners (e.g. USAID, UNFPA, IPPF)||Bulk delivery of oral contraceptives, injections and implants for family planning programs in developing countries in agreement with partners||Figures for 2011: |
Hormone implant: 1.61 million; CYPs: 5.64 million
Oral contraceptives: 118.56 million; CYPs: 8.47 million
Injections: 4.53 million; CYPs: 1.13 million Total CYPs in 2011: 15.24 million
All CYPs are calculated using the MSI Impact Calculator (Version 1.2) Target defined in 2009 and met in 2010; the level was sustained in 2011
|Neglected Diseases||Implemented measures||Results in 2011|
|Support the WHO|
• in tackling Chagas and
• in treating African sleeping sickness
|Extension of cooperation with the WHO in the fight against Chagas and doubling of the provision of nifurtimox for Chagas treatment from 500,000 to 1 million tablets per year from 2012 to 2017, a total of 5 million tablets and US$1.5 million during the entire period||Figures for Chagas: |
2011: Number of nifurtimox tablets distributed according to the WHO: 488,100 worldwide
Patients treated with nifurtimox: 1,212
| ||Annual provision of 400,000 tablets containing nifurtimox to the WHO for the nifurtimox/eflornithine combination therapy of African sleeping sickness from 2009 to 2012 |
Plans to extend the contract
Bayer participation in the Bill & Melinda Gates Foundation’s initiative “London Declaration on NTDs (Neglected Tropical Diseases)” on January 30, 2012 for the elimination of neglected tropical diseases by 2020
|African sleeping sickness: A combination therapy involving drugs containing the active ingredients nifurtimox and eflornithine for the treatment of this disease has been placed on the WHO’s Essential Drug List |
2011: 403,700 tablets containing nifurtimox distributed by the WHO
4,500 patients treated
The report on the WHO’s control and monitoring program on African sleeping sickness from 2011 indicates that:
- The number of cases for both forms of the disease has declined steadily
- The combination therapy of eflornithine and nifurtimox has made an important contribution to this decline
- The chances of eliminating the sickness are high
|Conduct research into shortening the duration of tuberculosis therapy together with the Global Alliance for TB Drug Development|| ||Patient recruitment for the ReMOXTB**** study concluded mid-January 2012|
|New cooperation with the WHO in tackling TB||Cooperation between Bayer, the WHO and the Stop Tuberculosis (TB) Partnership to tackle multi-resistant tuberculosis||Bayer made 620,000 tablets of the antibiotic moxifloxacin available in 2011 |
to treat TB in China
* CYP = Couple Years of Protection. CYP is the number of couples who used the provided contraceptives for a year.
** MSI Impact Calculator: Marie Stopes International (MSI) is one of the biggest international organizations committed to the support of family planning and reproductive health.
The Impact Calculator is a method for controlling the influence of, for example, family planning programs. More information is available at http://www.mariestopes.org/
*** Outlet: pharmacies or drug-dispensing outlets
**** ReMOXTB = rapid evaluation of moxifloxacin in the treatment of sputum smear positive tuberculosis. (This study investigates a short, fast therapy involving moxifloxacin for the treatment of tuberculosis.)